Never inject in the same spot twice in a row
Mounjaro patients histories are a bit of a mix: 56% of patients have evidence of a diabetes treatment before starting Mounjaro, but 39% are nave to any prior diabetes pharmaceutical
Clinical Pharmacokinetics, 60 (10), 13351348
Thats why we need more pharmacologic options to be used alongside lifestyle. With limited data on the use of GLP-1RAs in pediatric MASLD, Tou and mentor, Jennifer Panganiban, MD, attending gastroenterologist and director of the Non Alcoholic Fatty Liver Disease Program at Children's Hospital of Philadelphia, conducted a retrospective cohort study of patients aged younger than 21 years who started treatment with GLP-1RAs at Childrens Hospital of Philadelphia from Jan
Clinical applications reflect these differences
These factors that decrease GLP-1 correlate with the rise in obesity at a national and global level